Covid Vaccine Phase 3
New brunswick n j september 23 2020 johnson johnson nyse.
Covid vaccine phase 3. The first set of results from our phase 3 covid 19 vaccine trial provides the initial evidence of our vaccine s ability to prevent covid 19. Jnj the company today announced the launch of its large scale pivotal multi country phase 3 trial ensemble for its covid 19 vaccine candidate jnj 78436735 being developed by its janssen pharmaceutical companies. The vaccine known as mrna 1273 was co developed by the cambridge massachusetts based biotechnology company moderna inc and the national institute of allergy and infectious diseases niaid part of the national institutes of health. A vaccine jointly developed by pfizer and biontech was 90 effective in preventing covid 19 infections in ongoing phase 3 trials the companies announced monday.
With more than 200 000 americans dead from covid 19 pharmaceutical companies are racing to roll out vaccines to halt the coronavirus pandemic. Today is a great day for science and humanity.